Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
NCT Number: NCT01062178
Patients with an incidentally discovered small renal masses (SRM) < 4 cm in diameter are included. All patients will undergo biopsy for tissue diagnosis. Most patients will be followed by imaging. Study intervention includes low MI US to be performed following both bolus and infusion injection of Definity contrast. Presence and absence of vascularity, pattern of vascularity, and TIC values will be correlated with the final pathology to find features differentiating benign from malignant masses.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 2
Toronto, Ontario, M5G 2C4, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
Time frame: 12 to 18 months
University Health Network, Toronto
Other
The Comparison of Accuracy of Contrast Enhanced Ultrasound on Diagnosis of Small Renal Masses and Distinguishing Renal Cell Carcinomas From Other Renal Masses, With Biopsy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial DetailsNCT02009449
Adenocarcinoma, Adnexal Diseases
Los Angeles, California, United States
View Trial DetailsNCT05256472
Adenocarcinoma, Carcinoma
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT03294083
Adenocarcinoma, Carcinoma
Irvine, California, United States
View Trial Details